Business:
NASH therapy
Drug notes:
Also Clin2 MASH cirrhosis; undisclosed programs RD undisclosed
About:
Akero Therapeutics is developing treatments for patients with serious metabolic diseases. Many metabolic diseases, such as non-alcoholic steatohepatitis (NASH), are marked by high unmet medical need. NASH is caused by excess storage of fat in the liver which causes liver inflammation and scarring. Akero is using a licensed engineered protein called efruxifermin (EFX) and developing it to treat the metabolic dysfunction that occurs in NASH patients. EFX is a differentiated Fc-FGF21 fusion protein that mimics native FGF21 to alleviate cellular stress and regulate metabolism. Building on positive Phase 2a results, EFX is now being used in Phase 2b clinical trials in pre-cirrhotic patients.
Clinical Trial Management Associate Remote|3 days ago
Clinical Trial Manager/Sr. Clinical Trial Manager ... Remote|3 days ago
Assistant Controller Remote|3 days ago
Senior Clinical Trial Manager Remote|3 days ago
Laboratory Clinical Trial Management Associate (CT... Remote|72 days ago
Director, Clinical Development Remote|85 days ago